Difference between revisions of "Tafasitamab (Monjuvi)"
Jump to navigation
Jump to search
m |
|||
| Line 7: | Line 7: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *7/31/2020: Granted accelerated approval in combination with lenalidomide for adult patients with relapsed or refractory [[Diffuse large B-cell lymphoma|diffuse large B-cell lymphoma (DLBCL) not otherwise specified]], including [[Transformed lymphoma|DLBCL arising from low grade lymphoma]], and who are not eligible for autologous stem cell transplant. | + | *7/31/2020: Granted accelerated approval in combination with lenalidomide for adult patients with relapsed or refractory [[Diffuse large B-cell lymphoma|diffuse large B-cell lymphoma (DLBCL) not otherwise specified]], including [[Transformed lymphoma|DLBCL arising from low grade lymphoma]], and who are not eligible for autologous stem cell transplant. ''(Based on L-MIND)'' |
==Also known as== | ==Also known as== | ||
Revision as of 17:55, 10 May 2021
Mechanism of action
Anti-CD19 antibody with an engineered Fc region to enhance Fcγ receptor binding affinity
Diseases for which it is used
History of changes in FDA indication
- 7/31/2020: Granted accelerated approval in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant. (Based on L-MIND)
Also known as
- Code names: MOR208, MOR00208, XmAb5574
- Generic name: tafasitamab-cxix
- Brand name: Monjuvi